Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 294

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Serum miR-200c Is a Novel Prognostic and Metastasis-Predictive Biomarker in Patients With Colorectal Cancer

Open access
Toiyama, Yuji, Hur, Keun, Tanaka, Koji, Inoue, Yasuhiro, Kusunoki, Masato, Boland, C. Richard, Goel, Ajay·2014·Annals of Surgery

Abstract

In Brief Objective: To evaluate the ability of epithelial-to-mesenchymal transition–related microRNAs (miRNAs) as serum biomarkers for prognosis and prediction of metastasis in patients with colorectal cancer (CRC). Background: Epithelial-to-mesenchymal transition–related miRNAs drive CRC progression and metastasis. However, their potential as serum biomarkers in CRC has not been studied. Methods: This was a 3-phase study using 446 colorectal specimens. In the first phase, we selected candidate miRNAs associated with metastasis by analyzing the expression of 4 miR-200 family members (miR-200b, -200c, -141, and -429) in serum samples from 12 patients with stage I and IV CRC. The second phase involved independent validation of candidate miRNAs in serum from 182 patients with CRC and 24 controls. Finally, we analyzed expression in matched 156 tumor tissues from 182 patients with CRC and an independent set of 20 matched primary CRC and corresponding liver metastases to identify the source of circulating miRNAs. Results: After initial screening, miR-200c was selected as the candidate serum miRNA best associated with metastasis. Validation analysis revealed that serum miR-200c levels were significantly higher in stage IV than in stage I–III CRCs. High serum miR-200c demonstrated a significant positive correlation with lymph node metastasis, distant metastasis, and prognosis (P = 0.0026, P = 0.0023, and P = 0.0064, respectively). More importantly, serum miR-200c was an independent predictor for lymph node metastasis (odds ratio: 4.81, 95% confidence interval: 1.98–11.7, P = 0.0005) and tumor recurrence (hazard ratio: 4.51, 95% confidence interval: 1.56–13.01, P = 0.005) and emerged as an independent prognostic marker for CRC (hazard ratio: 2.67, 95% confidence interval: 1.28–5.67, P = 0.01). Conclusions: Serum miR-200c has strong potential to serve as a noninvasive biomarker for CRC prognosis and predicting metastasis. We demonstrated that serum miR-200c levels increased in a stage-dependent manner and were significantly higher in stage IV patients. Furthermore, high serum miR-200c expression was significantly associated with tumor metastasis (lymph node, liver, or other organs) and emerged as independent factors for reduced disease-free and overall survival. Finally, we provide potential insights into the origin of high serum miR-200c levels in patients with advanced CRC and metastasis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/sla.0b013e3182a6909d

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 294

Metadata

Authors
Toiyama, Y., Hur, K., Tanaka, K., Inoue, Y., Kusunoki, M., Boland, C. R., & Goel, A.
Venue
Annals of Surgery
Published
2014-04
Volume
259
Issue
4
Pages
735-743
ISSN
0003-4932 (ISSN-L)
OpenAlex
W2005154499
Cited by
294
References
27
FWCI
10.76
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serum miR-200c Is a Novel Prognostic and Metastasis-Predictive Biomarker in Patients With Colorectal Cancer. https://app.cochat.ai/papers/10.1097/sla.0b013e3182a6909d
The paper
Toiyama, Y., Hur, K., Tanaka, K., Inoue, Y., Kusunoki, M., Boland, C. R., & Goel, A. (2014). Serum miR-200c Is a Novel Prognostic and Metastasis-Predictive Biomarker in Patients With Colorectal Cancer. Annals of Surgery. https://doi.org/10.1097/sla.0b013e3182a6909d

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.